Infectious disease Archives

News and Trends 4 Dec 2017

Israeli Biotech Gets $30M Backing for its Immune Modulators for Severe Infections

Atox Bio develops immune modulators to save patients with severe infections. An oversubscribed Series F financing will support its lead candidate through a Phase II trial. Atox Bio, which has operations in the US and Israel, develops immune modulators for patients with severe infections. The biotech was established at the Hebrew University of Jerusalem and Yissum. […]

December 4, 2017 - 2 minutesmins - By Alex Dale

In Depth 14 Nov 2017

The World’s Deadliest Diseases: How is Biotech Fighting Them?

With the recent outbreaks of plague in Madagascar and Ebola in West Africa, two terrifying diseases are back in the news. But these are not the only infections that are inevitably fatal if untreated, or, even worse, for which no therapy is available yet. Though mostly rare, deadly diseases are closer than you think. Plague […]

November 14, 2017 - 7 minutesmins - By Ute Boronowsky

News and Trends 6 Nov 2017

Austrian Biotech’s Vaccine Against Tropical Virus Moves Nicely Through Phase II

Chikungunya fever could be the next big global outbreak. Reassuringly, Themis’ vaccine has so far performed well in a Phase II study. Vienna-based biotech, Themis, develops urgently needed vaccines against diseases, which have the potential to be the next global outbreak. The company has announced encouraging preliminary Phase II results for its vaccine against chikungunya […]

November 6, 2017 - 3 minutesmins - By Alex Dale

News and Trends 12 Oct 2017

No More Seasonal Flu Shots: British Biotech’s Universal Antiviral Raises £13M

VirionHealth kicks off the development of a broad spectrum antiviral for all influenza strains and other viruses like RSV with a £13M investment in Series A. VirionHealth is developing a new type of antiviral therapy with the potential to target multiple types of viruses at once. The treatment is based on natural antivirals called defective interfering viruses. They consist […]

October 12, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 12 Oct 2017

Deadly Parasite Could be Stopped by Scottish Researchers’ Discovery

A study in Scotland has improved our understanding of how a dangerous parasite functions, creating a new target for combatting deadly infections. Research from the University of Edinburgh has identified a therapeutic target in Leishmania, a parasite that infects 1 million people each year, resulting in 20,000-30,000 deaths. The study, published in the Journal of Molecular Biology, used clever […]

October 12, 2017 - 3 minutesmins - By Alex Dale

News and Trends 18 Sep 2017

British Unicorn Gets $40M Boost from Bill & Melinda Gates Foundation

The Bill & Melinda Gates Foundation have injected $40M (€33M) into Immunocore to accelerate the development of its immunotherapies for infectious diseases. Investment from the Bill & Melinda Gates Foundation will support the development of Immunocore’s ImmTAV and ImmTAB TCR-based technologies, which help the immune system to target virally and bacterially infected cells, respectively. In particular, […]

September 18, 2017 - 2 minutesmins - By Alex Dale

More News! 14 Sep 2017

Could Using Bacteria’s Own Killing Capacity be a Knockout Blow in the Fight Against Antibiotic Resistance?

Scientists in the UK and US have identified how in-fighting between bacteria could provide a new treatment for hospital-acquired infections. Clostridium difficile is a common cause of hospital-acquired infections, which kill almost 4,000 people in Europe each year. Scientists at the University of Sheffield, the University of Glasgow, and California-based biotech AvidBiotics Corp have discovered that C. difficile uses nanomolecular […]

September 14, 2017 - 2 minutesmins - By Alex Dale

News and Trends 12 Sep 2017

France Invests €15M in Developing a New Generation of Antibiotics

Deinove has received funding from Bpifrance to work on the discovery of the next generation of antibiotics to fight antibiotic-resistant pathogens. The Investments for the Future Program, operated by the French public investment bank Bpifrance, has granted €14.6M to the Antibiotics against Resistant Infectious Germs (AGIR) project, carried out by the Deinove group in collaboration […]

September 12, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

destiny pharma new antibiotics mrsa london stock1

News and Trends 4 Sep 2017

British Biotech Developing New Antibiotics Enters the London Stock Exchange

Destiny Pharma has started trading on the London Stock Exchange to support its search for new antibiotics that can fight resistant bacteria like MRSA. Destiny Pharma, based in Brighton, UK, has entered the AIM market of the London Stock Exchange with an initial placement of £15.3M (€16.7M), which put its starting market cap at £65.4M […]

September 4, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 1 Aug 2017

Potential Herpes Cure from Germany Fast-Tracked for Patients with Weak Immune Systems

AiCuris’ Pritelivir has now secured FDA endorsement in the form of a Fast Track Designation in immuno-compromised patients. Based in Wuppertal, Germany, and spun out from Bayer, AiCuris is focused on curing infectious diseases. Its lead candidate for herpes simplex viruses 1 and 2 (HSV-1 and -2), pritelivir, has been watched closely for its promise […]

August 1, 2017 - 2 minutesmins - By Editorial Team

CureVac mrna vaccine rabies Ingmar Hoerr

News and Trends 26 Jul 2017

German Biotech Publishes First-in-Human Data on Rabies mRNA Vaccine

CureVac has published proof-of-concept data for an mRNA rabies vaccine that could open the door for a new generation of better and cheaper vaccines. CureVac, based in Tübingen, Germany, is a pioneer in the development of therapeutic mRNA technology. The company has published today in The Lancet proof-of-concept data from a Phase I trial testing CV7201, […]

July 26, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

In Depth 25 Jul 2017

Trouble in Paradise: How Biotech is Fighting Tropical Diseases

Tropical diseases are often neglected until an outbreak causes worldwide panic. Here’s how European biotech is preparing for the next one. “What we really need is a very fast and cheap way to develop vaccines,” biotech godfather Greg Winter told me earlier this year. Such precautionary measures may well be on our minds as Europe […]

July 25, 2017 - 6 minutesmins - By Evelyn Warner

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Infectious disease

Israeli Biotech Gets $30M Backing for its Immune Modulators for Severe Infections

The World’s Deadliest Diseases: How is Biotech Fighting Them?

Austrian Biotech’s Vaccine Against Tropical Virus Moves Nicely Through Phase II

No More Seasonal Flu Shots: British Biotech’s Universal Antiviral Raises £13M

Deadly Parasite Could be Stopped by Scottish Researchers’ Discovery

British Unicorn Gets $40M Boost from Bill & Melinda Gates Foundation

Could Using Bacteria’s Own Killing Capacity be a Knockout Blow in the Fight Against Antibiotic Resistance?

France Invests €15M in Developing a New Generation of Antibiotics

British Biotech Developing New Antibiotics Enters the London Stock Exchange

Potential Herpes Cure from Germany Fast-Tracked for Patients with Weak Immune Systems

German Biotech Publishes First-in-Human Data on Rabies mRNA Vaccine

Trouble in Paradise: How Biotech is Fighting Tropical Diseases

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!